Scinai Immunotherapeutics Ltd. (SCNI) has entered into a $2.61 million private placement financing agreement, strengthening its cash position as it advances its inflammation and immunology pipeline and expands its contract development and manufacturing (CDMO) services platform.
The financing includes the purchase and sale of 5,208,333 American Depositary Shares (ADSs) at $0.48 per ADS, each representing 4,000 ordinary shares. Investors will also receive Series A warrants to purchase up to 5,208,333 ADSs at an exercise price of $0.48 per ADS, exercisable immediately for two years, and Series B warrants to purchase an additional 5,208,333 ADSs at an exercise price of $0.55, exercisable immediately for five years.
In a parallel warrant inducement agreement, an existing institutional investor agreed to immediately exercise 229,310 ADS warrants at $0.48 per ADS. In return, the investor will receive 458,621 new unregistered warrants with a five-year term and an exercise price of $0.55.
Scinai expects the combined transactions to generate approximately $2.61 million in gross proceeds, before fees and expenses. Closing is anticipated on or about April 27, 2026, subject to customary conditions.
The company stated that the funds will support the expansion of its CDMO platform, advancement of customer programs, and selective investment in its immunotherapy pipeline, which focuses on innovative inflammation and immunology therapeutics. Scinai noted that the financing will help drive execution of its broader growth strategy.
A.G.P./Alliance Global Partners acted as the sole financial advisor for the transaction. The securities were offered under exemptions from registration pursuant to Section 4(a)(2) and Regulation D of the Securities Act.
SCNI has traded between $0.45 and $6.18 over the past year. The stock is currently trading at $0.82, up 81.10%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.